Related Experiment Video
Updated: Jun 11, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents
K J Harrington1, R Kazi, S A Bhide
1Head and Neck Unit, The Royal Marsden Hospital, London and Surrey, The Institute of Cancer Research, 237 Fulham Road, London, United Kingdom.
Abstract:
Despite significant improvements in the treatment and outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) that have resulted from technological advances in radiation delivery and the use of cytotoxic chemotherapy, there is still a pressing need for novel therapies. In the last two decades, our understanding of the molecular biological basis of cancer has provided us with a new framework for developing specific targeted therapies. It is likely that the next wave of developments will include active small molecule inhibitors of epidermal growth factor receptor (EGFR) (and other members of the c-erbB family of receptors), antiangiogenic agents, and drugs that can increase proapoptotic signaling in cancer cells. As with cetuximab, it is most likely that these new agents will first find a niche in the context of combination regimens with standard anticancer therapeutics.
Insights
Novel targeted therapies are needed for squamous cell carcinoma of the head and neck (SCCHN). Future treatments may involve epidermal growth factor receptor (EGFR) inhibitors and antiangiogenic agents, likely combined with standard therapies.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Squamous cell carcinoma of the head and neck (SCCHN) treatment has improved but requires novel therapies.
- Advances in radiation delivery and chemotherapy have enhanced patient outcomes.
- A deeper understanding of cancer's molecular basis drives new therapeutic strategies.
Purpose of the Study:
- To explore emerging targeted therapies for SCCHN.
- To identify potential new drug classes for head and neck cancer treatment.
- To discuss the role of novel agents in combination regimens.
Main Methods:
- Review of molecular mechanisms in SCCHN.
- Analysis of emerging targeted therapy classes.
- Discussion of combination therapy strategies.
Main Results:
- Small molecule inhibitors of epidermal growth factor receptor (EGFR) and c-erbB family receptors show promise.
- Antiangiogenic agents represent a potential new therapeutic avenue.
- Drugs enhancing proapoptotic signaling could offer new treatment options.
Conclusions:
- Targeted therapies, including EGFR inhibitors and antiangiogenic agents, are the next frontier for SCCHN.
- These novel agents are likely to be integrated into combination regimens with existing treatments.
- Further research into molecularly targeted drugs is crucial for advancing SCCHN care.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers